Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Shares Spike for Second Time in a Week

NEW YORK (GenomeWeb News) – Shares of Compugen jumped 35 percent in early Monday trade on the Nasdaq after the firm announced that it had a new drug target for multiple epithelial tumors using its Monoclonal Antibody Targets Discovery Platform.

The firm's stock rose $1.42 to $5.50 within the first 20 minutes of the market's open. It was the second such spike in Compugen's stock within the past week.

Last week, its shares rose 62 percent in one day after it announced a deal to screen peptide candidates for three Pfizer drug targets.

Compugen said today that the new drug target, CGEN-671, is a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody therapies are in clinical development by others. It said that it has already filed patent applications covering the splice variant and its various therapeutic and diagnostic uses.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.